Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells $2,710,857.12 in Stock

Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca sold 20,784 shares of Merck & Co., Inc. stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the completion of the transaction, the executive vice president owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $135.78 on Friday. The stock has a market capitalization of $334.98 billion, a PE ratio of 108.62, a price-to-earnings-growth ratio of 5.85 and a beta of 0.19. The business’s fifty day moving average price is $125.54 and its 200 day moving average price is $119.94. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.06. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $135.97.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the prior year, the company earned $2.13 earnings per share. The firm’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Argus upped their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. Barclays boosted their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Finally, Bank of America lifted their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $135.50.

Institutional Trading of Merck & Co., Inc.

Several large investors have recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth $25,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $26,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $26,000. High Note Wealth LLC raised its stake in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. in the fourth quarter worth about $31,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.